887 related articles for article (PubMed ID: 32618086)
1. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
2. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
4. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
Greene SJ; Butler J; Kosiborod MN
Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
[TBL] [Abstract][Full Text] [Related]
5. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund LH; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Nov; 22(11):1984-1986. PubMed ID: 33068051
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
8. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
9. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
Herrington WG; Savarese G; Haynes R; Marx N; Mellbin L; Lund LH; Dendale P; Seferovic P; Rosano G; Staplin N; Baigent C; Cosentino F
Eur J Heart Fail; 2021 Aug; 23(8):1260-1275. PubMed ID: 34184823
[TBL] [Abstract][Full Text] [Related]
10. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
Nakagawa Y; Kuwahara K
J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
[TBL] [Abstract][Full Text] [Related]
12. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
18. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
20. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
